 This is a copy of a chat between Claude and Lars S. Content may include unverified or unsafe content that do not represent the views of Anthropic. Shared snapshot may contain attachments and data not displayed here. Report

**LS** What genes interact with the drug Ibrutinib, and which of those genes have specific variants in CIViC associated with sensitivity or resistance?

I'll help you find genes that interact with Ibrutinib and then check which of those genes have variants in CIViC associated with sensitivity or resistance.

**L** `get_gene_interactions_for_drug_list`

Now let me search CIViC for evidence about sensitivity and resistance for the top interacting genes:

**L** `get_variant_evidence`

**L** `get_variant_evidence`

Now let me also check for PLCG2 variants specifically, as this was the top-scoring gene for drug interactions:

**L** `get_variant_evidence`

Let me also check for CIViC assertions to get the most validated clinical evidence:

**L** `get_variant_assertions`

Here's a comprehensive summary of what I found:

## Genes That Interact with Ibrutinib

Based on DGIdb data, the top genes interacting with Ibrutinib include:

Gene	Interaction Score	Interaction Type	Key Sources
PLCG2	4.61	-	<a href="#">CGI</a> , <a href="#">DoCM</a> , <a href="#">PMID:24869598</a>
MYD88	1.54	-	<a href="#">CGI</a> , <a href="#">CIViC</a> , <a href="#">PharmGKB</a>

Gene	Interaction Score	Interaction Type	Key Sources
BTK	0.38	Inhibitor (inhibitory)	<a href="#">Multiple sources</a> including CIViC, TTD, CGI, ChEMBL
Other genes: BMX, TEC, LYN, SMARCA4, CSF3R, EPHA8, etc.			

# CIViC Variants Associated with Ibrutinib Response

## Sensitivity/Response Variants

Gene	Variant	Disease	Evidence Level	CIViC Link
MYD88	L265P	Lymphoplasmacytic Lymphoma	B (Clinical)	<a href="#">EID:986</a> , <a href="#">PMID:25853747</a>
BTK	Expression	B-cell ALL	D (Preclinical)	<a href="#">EID:9287</a> , <a href="#">PMID:28031181</a>

## Resistance Variants

Gene	Variant	Disease	Evidence Level	CIViC Link
BTK	C481S	CLL	B (Clinical)	<a href="#">EID:436</a> , <a href="#">PMID:24869598</a> ; <a href="#">EID:1770</a> , <a href="#">PMID:26182309</a>
BTK	T316A	CLL	C (Case study)	<a href="#">EID:1985</a> , <a href="#">PMID:27626698</a>
PIM1	L2V, P81S, S97N	DLBCL-ABC	D (Preclinical)	<a href="#">EID:9945-9947</a> , <a href="#">PMID:27904766</a>

# Key Findings

**Overlapping genes** (appear in both DGIdb drug interactions AND CIViC with sensitivity/resistance evidence):


## 1. BTK - The primary target of ibrutinib

- **Resistance:** C481S mutation (most common acquired resistance mechanism in CLL - found in ~80% of resistant cases) and T316A
- **Sensitivity:** BTK expression associated with response in B-ALL

## 2. MYD88 - Key interacting gene

- **Sensitivity:** L265P mutation associated with better response in Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma

**PLCG2** - Although it has the highest interaction score in DGIdb and is known to be involved in ibrutinib resistance (mutations found in patients with acquired resistance), I did not find specific PLCG2 variant evidence entries in CIViC for ibrutinib at this time.

 Turn on web search in Search and tools

Start your own conversation

not be accurate or up to date.